UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Hypercholesterolemia and atherosclerosis in primary biliary cholangitis (primary biliary cirrhosis)

Authors
Steven Flamm, MD
Andre A Kaplan, MD
Raoul Poupon, MD
Sanjiv Chopra, MD, MACP
Section Editor
Keith D Lindor, MD
Deputy Editor
Anne C Travis, MD, MSc, FACG, AGAF

INTRODUCTION

Hypercholesterolemia is a common feature of primary biliary cholangitis (PBC; previously referred to as primary biliary cirrhosis) and other forms of cholestatic liver disease. The mechanism of hyperlipidemia in cholestatic disorders is different from that in other conditions as unusual lipoprotein particles, such as lipoprotein X, may accumulate and levels of HDL cholesterol are typically elevated. An important question is whether these patients are at risk for the complications of hypercholesterolemia? The available data suggest that patients with PBC and hypercholesterolemia are not at increased risk of atherosclerosis. However, patients with early stage PBC may have independent abnormalities of lipid metabolism and may be exposed to increased cardiovascular risk due to their normal life expectancy under ursodeoxycholic acid (UDCA) treatment. If there is any question, PBC patients should have fasting lipoprotein profiles and assessment of concomitant risk factors for atherosclerosis.

This topic will review hypercholesterolemia and atherosclerosis in patients with primary biliary cholangitis. Other issues related to hypercholesterolemia and the role of hypercholesterolemia in the development of atherosclerosis are discussed separately. (See "Screening for lipid disorders" and "Treatment of lipids (including hypercholesterolemia) in secondary prevention" and "Overview of the risk equivalents and established risk factors for cardiovascular disease" and "Pathogenesis of atherosclerosis".)

PREVALENCE

Initial studies suggested that the total plasma cholesterol was elevated in 50 percent of patients with PBC using normal values that ranged from 218 mg/dL to 300 mg/dL (5.7 to 7.9 mmol/L) [1]. The mean plasma cholesterol concentrations in this study were 285 mg/dL (7.4 mmol/L) in asymptomatic patients and 377 mg/dL (9.8 mmol/L) in symptomatic patients. Later studies confirmed these findings; 76 percent and 96 percent of asymptomatic and symptomatic patients had total plasma cholesterol values above 200 mg/dL (5.2 mmol/L), respectively [2-4]. However, the range of values was extremely wide, from 120 mg/dL (3.1 mmol/L) to 1775 mg/dL (46.1 mmol/L) in one report of 284 patients [5].

CHOLESTEROL PROFILE

Some studies have found elevated very low density lipoprotein (VLDL) and low density lipoprotein (LDL) levels, as well as markedly elevated high density lipoprotein (HDL) levels in some patients with early (histologic) stage PBC [4,5]. In later stage disease, the LDL levels increased further, but HDL levels fell markedly. A larger study reached similar conclusions: both LDL and total cholesterol levels increased with worsening histologic stage; the levels of HDL and apolipoprotein A-1, which is associated with HDL, were elevated at all stages but fell in patients with cirrhosis (though they may still be elevated compared with age-matched controls) [3]. Triglyceride levels were normal or slightly elevated.

Some of the excess LDL in PBC is composed of an abnormal lipoprotein particle (lipoprotein X), which is seen in advanced cholestatic liver disease and marked hyperbilirubinemia [6]. It is rich in free cholesterol and phospholipids [3,5,7]. Lipoprotein X is believed to reduce the atherogenicity of LDL cholesterol by preventing LDL oxidation [8]. Prolonged LDL oxidation has been demonstrated in patients with PBC, and normalizes following liver transplantation [6].

     

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Oct 15 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Dickson, E, Fleming, C, Ludwig, J. Primary biliary cirrhosis. In: Progress in Liver Diseases, Vol. 6, Popper, H, Schaffner, F (Eds), Grune and Stratton, New York 1978. p.487.
  2. Propst A, Propst T, Lechleitner M, et al. Hypercholesterolemia in primary biliary cirrhosis is no risk factor for atherosclerosis. Dig Dis Sci 1993; 38:379.
  3. Jahn CE, Schaefer EJ, Taam LA, et al. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 1985; 89:1266.
  4. Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002; 51:265.
  5. Crippin JS, Lindor KD, Jorgensen R, et al. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology 1992; 15:858.
  6. Su TC, Hwang JJ, Kao JH. Hypercholesterolemia in primary biliary cirrhosis. N Engl J Med 2007; 357:1561.
  7. Rosenson RS, Baker AL, Chow MJ, Hay RV. Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis. Gastroenterology 1990; 98:1351.
  8. Chang PY, Lu SC, Su TC, et al. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res 2004; 45:2116.
  9. Gregory WL, Game FL, Farrer M, et al. Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis. Atherosclerosis 1994; 105:43.
  10. Peters MG, Hoffnagle JH, McGarvey C, et al. Primary biliary cirrhosis: management of an unusual case with severe xanthomata by hepatic transplantation. J Clin Gastroenterol 1989; 11:694.
  11. Thomas PK, Walker JG. Xanthomatous neuropathy in primary biliary cirrhosis. Brain 1965; 88:1079.
  12. Van Dam GM, Gips CH. Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures. Scand J Gastroenterol 1997; 32:77.
  13. Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 2007; 194:293.
  14. Allocca M, Crosignani A, Gritti A, et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 2006; 55:1795.
  15. Solaymani-Dodaran M, Aithal GP, Card T, West J. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study. Am J Gastroenterol 2008; 103:2784.
  16. Floreani A, Variola A, Niro G, et al. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am J Gastroenterol 2008; 103:1959.
  17. Floreani A, Cazzagon N, Franceschet I, et al. Metabolic syndrome associated with primary biliary cirrhosis. J Clin Gastroenterol 2015; 49:57.
  18. Poupon RE, Ouguerram K, Chrétien Y, et al. Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology 1993; 17:577.
  19. Del Puppo M, Galli Kienle M, Crosignani A, et al. Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration. J Lipid Res 2001; 42:437.
  20. Schaffner F. Paradoxical elevation of serum cholesterol by clofibrate in patients with primary biliary cirrhosis. Gastroenterology 1969; 57:253.
  21. Iwasaki S, Ohira H, Nishiguchi S, et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol Res 2008; 38:557.
  22. Rudic JS, Poropat G, Krstic MN, et al. Bezafibrate for primary biliary cirrhosis. Cochrane Database Syst Rev 2012; 1:CD009145.
  23. Liberopoulos EN, Florentin M, Elisaf MS, et al. Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J 2010; 4:120.
  24. Stojakovic T, Putz-Bankuti C, Fauler G, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007; 46:776.
  25. Ritzel U, Leonhardt U, Näther M, et al. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 2002; 36:454.
  26. Kamisako T, Adachi Y. Marked improvement in cholestasis and hypercholesterolemia with simvastatin in a patient with primary biliary cirrhosis. Am J Gastroenterol 1995; 90:1187.
  27. Kurihara T, Akimoto M, Abe K, et al. Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin Ther 1993; 15:890.
  28. Abu Rajab MA, Kaplan MM. Statin use in primary biliary cirrhosis: Are they safe? (abstract). Gastroenterology 2007; 132:A732.
  29. Turnberg LA, Mahoney MP, Gleeson MH, et al. Plasmaphoresis and plasma exchange in the treatment of hyperlipaemia and xanthomatous neuropathy in patients with primary biliary cirrhosis. Gut 1972; 13:976.
  30. Kaplan AA, Halley SE, Reardon J, Sevigny J. One year's experience using a rotating filter for therapeutic plasma exchange. ASAIO Trans 1989; 35:262.